Atlas Trials

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Clinical trial NCT06378593 · RECRUITING

Trial details

NCT number
NCT06378593
Sponsor
3H (Suzhou) Pharmaceuticals Co., Ltd.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Solid Tumors With FGFR2 Alterations, Adult
Start date
2024-06-17
Primary completion
2028-06-16
Enrollment
130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.